

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Genscript Biotech Corporation

金斯瑞生物科技股份有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1548)

VOLUNTARY ANNOUNCEMENT RESEARCH AND DEVELOPMENT UPDATE

Reference is made to the voluntary announcements of Genscript Biotech Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) dated 28 October 2016 and 14 May 2017 in relation to the research and development results of chimeric antigen receptor T (“**CAR-T**”) cell technology in immunotherapy for cancer cure by Nanjing Legend Biotechnology Co., Ltd.* 南京傳奇生物科技有限公司 (“**Nanjing Legend**”), a wholly-owned subsidiary of the Company.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to further announce that on 5 June 2017, Nanjing Legend was invited to speak at the “News of the Day” press briefing arranged by The American Society of Clinical Oncology (“**ASCO**”) and was invited to present the results of the application of its proprietary CAR-T technology targeting multiple myeloma as “late breaking abstract” at the 2017 annual meeting of ASCO. Nanjing Legend was also interviewed by major international media on the research and development update. ASCO is the world’s leading professional organization for physicians and oncology professionals caring for people with cancer.

The clinical research and development yields promising results. As of May 2017, Nanjing Legend has applied its proprietary CAR-T technology to treat 35 relapsed or refractory multiple myeloma patients. Among the treated patients, 15 consistently achieved diagnostic criteria of “stringent complete response”, 12 achieved “very good partial response” and 6 achieved “partial response” and it is believed that many of these patients may proceed to eventually reaching “complete response” in the future with longer time of follow-up. One patient did not proceed with the clinical trial for unexpected onset of other serious disease and one patient had a relapse of extramedullary lesion but not of bone marrow disease. None of the treated patients had serious adverse event or fatal events, with only two of them experienced transient grade ≥ 3 adverse event. The clinical research results suggested that the CAR-T technology has the potential to bring curing solutions to multiple myeloma patients under a safe and effective treatment.

For a brief introduction of multiple myeloma and CAR-T cell therapy and the prospects of the Group’s proprietary CAR-T cell technology on its future business development, please refer to the Company’s announcements dated 28 October 2016 and 14 May 2017. The Group believes that the presentation at the 2017 annual meeting of ASCO enhances the international reputation of Nanjing Legend which will bring more opportunities to its business development in the future.

By order of the Board
Genscript Biotech Corporation
Zhang Fangliang
Chairman and Chief Executive Officer

Hong Kong, 6 June 2017

As at the date of this announcement, the executive Directors are Dr. Zhang Fangliang, Ms. Wang Ye and Mr. Meng Jiange; the non-executive Directors are Dr. Wang Luquan, Mr. Huang Zuie-Chin and Mr. Pan Yuexin; and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian and Ms. Zhang Min.

* *For identification purposes only*